Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease

Laboratory Investigation

Volumn 86, Issue 2, 2006, Pages 191-201

  Blair, Stephanie A ^a   Kane, Sunanda V ^a   Clayburgh, Daniel R ^a   Turner, Jerrold R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Crohn's disease; Myosin; Tight junctions; Tumor necrosis factor; Ulcerative colitis

Indexed keywords

MYOSIN LIGHT CHAIN KINASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENTERITIS; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; INTESTINE BIOPSY; INTESTINE EPITHELIUM; INTESTINE RESECTION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; UPREGULATION;

ADULT; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; MYOSIN-LIGHT-CHAIN KINASE; PHOSPHORYLATION;

EID: 30944443377     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700373     Document Type: Article

References (35)

1. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004;84:282-291.
2. Hollander D. Crohn's disease - a permeability disorder of the tight junction? Gut 1988;29:1621-1624.
3. Katz KD, Hollander D, Vadheim CM, et al. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 1989;97:927-931.
4. Ukabam SO, Clamp JR, Cooper BT. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. Digestion 1983;27:70-74.
5. Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 2000;119:1740-1744.
6. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-1439.
7. Yacyshyn BR, Meddings JB. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology 1995;108:132-137.
8. Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002;97:2000-2004.
9. Hiribarren A, Heyman M, L'Helgouac'h A, et al. Effect of cytokines on the epithelial function of the human colon carcinoma cell line HT29 cl 19A. Gut 1993;34:616-620.
10. Taylor CT, Dzus AL, Colgan SP. Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor alpha. Gastroenterology 1998;114:657-668.
11. Zolotarevsky Y, Hecht G, Koutsouris A, et al. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 2002;123:163-172.
12. Clayburgh DR, Barrett TA, Tang Y, et al. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest 2005;115:2702-2715.
13. Turner JR, Rill BK, Carlson SL, et al. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol 1997;273:C1378-C1385.
14. Scott KG, Meddings JB, Kirk DR, et al. Intestinal infection with Giardia spp. reduces epithelial barrier function in a myosin light chain kinase-dependent fashion. Gastroenterology 2002;123:1179-1190.
15. Yuhan R, Koutsouris A, Savkovic SD, et al. Enteropathogenic Escherichia coli-induced myosin light chain phosphorylation alters intestinal epithelial permeability. Gastroenterology 1997;113:1873-1882.
16. Wang F, Graham WV, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005;166:409-419.
17. Ma TY, Boivin MA, Ye D, et al. Mechanism of TNF-alpha modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 2005;288:G422-G430.
18. Clayburgh DR, Rosen S, Witkowski ED, et al. A differentiation-dependent splice variant of myosin light chain kinase, MLCK1, regulates epithelial tight junction permeability. J Biol Chem 2004;279:55506-55513.
19. +-glucose cotransport. Am J Physiol Gastrointest Liver Physiol 2001;281:G1487-G1493.
20. Graham WV, Wang F, Wang Y, et al. AP1-dependent transcriptional activation of myosin light chain kinase mediates IFNgamma- and TNFalpha-induced barrier dysfunction. FASEB J 2005;19, Abstract.
21. Micke P, Ohshima M, Tahmasebpoor S, et al. Biobanking of fresh frozen tissue: RNA is stable in non-fixed surgical specimens. Lab Invest 2006;86 (in press).
22. Prasad S, Mingrino R, Kaukinen K, et al. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 2005;85:1139-1162.
23. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-564.
24. Gitter AH, Bendfeldt K, Schulzke JD, et al. Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis. FASEB J 2000;14:1749-1753.
25. Musch MW, Clarke LL, Mamah D, et al. T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase. J Clin Invest 2002;110:1739-1747.
26. Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003;171:6164-6172.
27. Ma TY, Nguyen D, Bui V, et al. Ethanol modulation of intestinal epithelial tight junction barrier. Am J Physiol 1999;276:G965-G974.
28. Hollander D. Permeability in Crohn's disease: altered barrier functions in healthy relatives? Gastroenterology 1993;104:1848-1851.
29. Meddings JB, Sutherland LR, May GR. Intestinal permeability in patients with Crohn's disease. Gut 1994;35:1675-1676.
30. Jenkins RT, Ramage JK, Jones DB, et al. Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med 1988;11:151-155.
31. Gitter AH, Wullstein F, Fromm M, et al. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001;121:1320-1328.
32. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulceralive colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-1811.
33. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-28.
34. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999;116:1029-1034.
35. Kumar NB, Nostrant TT, Appelman HD. The histopathologic spectrum of acute self-limited colitis (acute infectious-type colitis). Am J Surg Pathol 1982;6:523-529.